Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4392744 | 0.82 | ENPP2 (0.47) | ENPP2PTGS2KMT2AGSRAKR1C3 | |
| Hydrochloric Acid SCHEMBL4395018 | 0.81 | ENPP2 (0.45) | ENPP2PTGS2KMT2AGSRAKR1C3 | |
| SCHEMBL3552882 | 0.81 | SMN1; SMN2 (0.52) | — | |
| SCHEMBL312685 | 0.80 | CA2 (0.60) | MAOBKMT2A | |
| SCHEMBL4394070 | 0.79 | MAPT (0.48) | — | |
| SCHEMBL410488 | 0.78 | SMN1; SMN2 (0.50) | KMT2A | |
| SCHEMBL4422041 | 0.78 | HDAC6 (0.57) | KMT2A | |
| SCHEMBL12348299 | 0.78 | HSD17B10 (0.36) | — | |
| SCHEMBL4394101 | 0.77 | HTT (0.58) | KMT2A | |
| SCHEMBL27101158 | 0.76 | RCE1 (0.41) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101321525-B | Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors | HOFFMANN LA ROCHE | 2013-01-30 | — | — | CN | disclosed |
| EP-2013201-B1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LTD (GB) | 2012-07-25 | — | — | EP | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| EP-1959951-B1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| CN-101321525-A | Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors | HOFFMANN LA ROCHE (CH) | 2008-12-10 | — | — | CN | disclosed |
| CN-101287729-A | GPCR agonists | PROSIDION LTD (GB) | 2008-10-15 | — | — | CN | disclosed |
| EP-1907383-A1 | GPCR AGONISTS | Prosidion Limited (GB) | 2008-04-09 | — | — | EP | disclosed |
| US-20080064728-A1 | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-03-13 | — | — | US | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| WO-2007003960-A1 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| EP-1623983-A1 | Heterocyclic compounds useful as DPP-IV inhibitors | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2006-02-08 | — | — | EP | disclosed |
| EP-1613304-A1 | DPP-IV INHIBITORS | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2006-01-11 | — | — | EP | disclosed |
| EP-1423120-A4 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORP (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6924284-B2 | PARP inhibitors | ICOS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
| CN-1568187-A | 2H-2,3-dinitrogen phenodiazine-1-ketone and using method thereof | ICOS CORP (US) | 2005-01-19 | — | — | CN | disclosed |
| EP-1423120-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| WO-2003015785-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | ENPP2 147/4885PTGS2 2800/4885MAOB 706/4885 |
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | ENPP2 848/4885PTGS2 1870/4885MAOB 1651/4885 |
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | ENPP2 1104/4885PTGS2 1776/4885MAOB 1227/4885 |
| US-20080064728-A1 | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | ENPP2 393/4885PTGS2 3335/4885MAOB 559/4885 |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GLP1R | ENPP2 886/4885PTGS2 1514/4885MAOB 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.